Pathogenetic mechanisms in thyroid follicular-cell neoplasia

Nature Reviews Cancer

Volumn 6, Issue 4, 2006, Pages 292-306

  Kondo, Tetsuo ^a,b,c   Ezzat, Shereen ^c,d   Asa, Sylvia L ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLINE; FIBRONECTIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; P CADHERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; PROTEIN RET; RAS PROTEIN; REGULATOR PROTEIN; TRANSCRIPTION FACTOR PAX8; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE REGULATION; CHROMOSOME REARRANGEMENT; CLONAL VARIATION; DISEASE ASSOCIATION; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC RISK; GENOMIC INSTABILITY; GERM LINE; HUMAN; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; THYROID CANCER; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CHROMOSOME ABERRATIONS; HUMANS; PROTO-ONCOGENE PROTEINS; THYROID NEOPLASMS;

EID: 33645307434     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1836     Document Type: Review

References (226)

1. Hundahl, S. A., Fleming, I. D., Fremgen, A. M. & Menck, H. R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83, 2638-2648 (1998).
2. American Cancer Society. Facts and Figures 2005 (American Cancer Society, Atlanta, 2005).
3. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
4. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs (eds DeLellis, R. A., Lloyd R. V., Heitz, P. U. & Eng, C.) [IARC Press, Lyon, 2004).
5. Liu, S., Semenciw, R., Ugnat, A. M. & Mao, Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br. J. Cancer 85, 1335-1339 (2001).
6. Marx, S. J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Rev. Cancer 5, 367-375 (2005).
7. LiVolsi, V. A. & Asa, S. L. The demise of follicular carcinoma of the thyroid gland. Thyroid 4, 233-236 (1994).
8. Kebebew, E., Greenspan, F. S., Clark, O. H., Woeber, K. A. & McMillan, A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103, 1330-1335 (2005).
9. Carcangiu, M. L., Zampi, G. & Rosai, J. Poorly differentiated ('insular') thyroid carcinoma. A reinterpretation of Langhans' 'wuchernde Struma'. Am. J. Surg. Pathol. 8, 655-668 (1984).
10. Rodriguez, J. M. et al. Insular carcinoma: an infrequent subtype of thyroid cancer. J. Am. Coll. Surg. 187, 503-508 (1998).
11. van der Laan B. F., Freeman J. L., Tsang R. W. & Asa S. L. The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma: evidence for dedifferentiation in tumor progression. Endocr. Pathol. 4, 215-221 (1993).
12. Hunt, J. L. et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am. J. Surg. Pathol. 27, 1559-1564 (2003).
13. Kazakov, V. S., Demidchik, E. P. & Astakhova, L. N. Thyroid cancer after Chernobyl. Nature 359, 21 (1992).
14. Williams, D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nature Rev. Cancer 2, 543-549 (2002).
15. Ron, E. et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 141, 259-277 (1995).
16. Ciampi, R. et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115, 94-101 (2005).
17. Harach, H. R., Escalante, D. A. & Day, E. S. Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis. Endocr. Pathol. 13, 175-181 (2002).
18. Yamashita, H. et al. Effects of dietary iodine on chemical induction of thyroid carcinoma. Acta. Pathol. Jpn 40, 705-712 (1990).
19. Gasbarri, A. et al. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. Br. J. Cancer 91, 1096-1104 (2004).
20. Prasad, M. L., Huang, Y., Pellegata, N. S., de la Chapelle, A. & Kloos, R. T. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45, 39-46 (2004).
21. Kawabata, W. et al. Estrogen receptors (α and β) and 17β-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Mod. Pathol. 16, 437-444 (2003).
22. Lee, M. L. et al. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J. 11, 113-121 (2005).
23. Haselkorn, T., Stewart, S. L. & Horn-Ross, P. L. Why are thyroid cancer rates so high in southeast asian women living in the United States? The bay area thyroid cancer study. Cancer Epidemiol. Biomarkers Prev. 12, 144-150 (2003).
24. Hemminki, K., Eng, C. & Chen, B. Familial risks for nonmedullary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 5747-5753 (2005).
25. Lupoli, G. et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 353, 637-639 (1999).
26. Lindor, N. M. & Greene, M. H. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J. Natl Cancer Inst. 90, 1039-1071 (1998).
27. Eng, C. Familial papillary thyroid cancer - many syndromes, too many genes? J. Clin. Endocrinol. Metab. 85, 1755-1757 (2000).
28. Johannessen, J. V., Sobrinho-Simoes, M., Lindmo, T. & Tangen, K. O. The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. Am. J. Clin. Pathol. 77, 20-25 (1982).
29. Belge, G. et al. Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. Cancer Genet. Cytogenet. 101, 42-48 (1998).
30. Castro, P. et al. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J. Pathol. 206, 305-311 (2005).
31. Sobrinho-Simoes, M. et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch. 447, 787-793 (2005).
32. Soares, P., dos Santos, N. R., Seruca, R., Lothe, R. A. & Sobrinho-Simoes, M. Benign and malignant thyroid lesions show instability at microsatellite loci. Eur. J. Cancer 33, 293-296 (1997).
33. Lazzereschi, D. et al. Microsatellite instability in thyroid tumours and tumour-like lesions. Br. J. Cancer 79, 340-345 (1999).
34. Saavedra, H. I. et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19, 3948-3954 (2000).
35. V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 65, 2465-2473 (2005).
36. Knauf, J. A. et al. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J. Biol. Chem. 281, 3800-3809 (2006).
37. Li, J. J. et al. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc. Natl. Acad. Sci. USA 101, 18123-18128 (2004).
38. Pati, D. et al. Hormone-induced chromosomal instability in p53-null mammary epithelium. Cancer Res. 64, 5608-5616 (2004).
39. Morgan, W. F. & Sowa, M. B. Effects of ionizing radiation in nonirradiated cells. Proc. Natl Acad. Sci. USA 102, 14127-14128 (2005).
40. Sieber, O. M., Heinimann, K. & Tomlinson, I. P. Genomic instability - the engine of tumorigenesis? Nature Rev. Cancer 3, 701-708 (2003).
41. Kimura, T. et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr. Rev. 22, 631-656 (2001).
42. Krohn, K. et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr. Rev. 26, 504-524 (2005).
43. Matsuo, K., Friedman, E., Gejman, P. V. & Fagin, J. A. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the α-subunit of Gs in human thyroid neoplasms. J. Clin. Endocrinol. Metab. 76, 1446-1451 (1993).
44. Spambalg, D. et al. Structural studies of the thyrotropin receptor and Gsα in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J. Clin. Endocrinol. Metab. 81, 3898-3901 (1996).
45. Goretzki, P. E. et al. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J. Surg. 16, 576-581 (1992).
46. Collins, M. T. et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gsα mutations. J. Clin. Endocrinol. Metab. 88, 4413-4417 (2003).
47. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005).
48. Takahashi, M. et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3, 571-578 (1988).
49. Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F. & Pachnis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367, 380-383 (1994).
50. Airaksinen, M. S. & Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nature Rev. Neurosci. 3, 383-394 (2002).
51. Tallini, G. amp; Asa, S. L. RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 8, 345-354 (2001).
52. Tallini, G. et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 4, 287-294 (1998).
53. Lam, A. K., Montone, K. T., Nolan, K. A. & Livolsi, V. A. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum. Pathol. 29, 565-568 (1998).
54. Sugg, S. L. et al. Oncogene profile of papillary thyroid carcinoma. Surgery 125, 46-52 (1999).
55. Musholt, T. J. et al. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 128, 984-993 (2000).
56. Nakazawa, T. et al. RET gene rearrangements [RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer 104, 943-951 (2005).
57. Sugg, S. L., Ezzat, S., Rosen, I. B., Freeman, J. L. & Asa, S. L. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 83, 4116-4122 (1998). One of the original reports that took advantage of distinct gene rearrangements in assigning clonal origin of multiple thyroid nodules in the same gland.
58. Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H. & Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690-1694 (1997). One of the original reports that documents the distinct pattern of gene rearrangements that are found in radiation-associated thyroid carcinomas.
59. Smida, J. et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int. J. Cancer 80, 32-38 (1999).
60. Nikiforova, M. N. et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290, 138-141 (2000). An elegant study that provides a structural basis for the predisposition of thyroid cells to radiation-induced chromosomal paracentric inversions.
61. Jhiang, S. M. et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137, 375-378 (1996). One of the earliest and more convincing lines of evidence for the role of RET/PTC rearrangement in thyroid cell transformation.
62. Powell, D. J. Jr et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 58, 5523-5528 (1998).
63. La Perle, K. M., Jhiang, S. M. & Capen, C. C. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am. J. Pathol. 157, 671-677 (2000).
64. Corvi, R. et al. Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization. Lab. Invest. 81, 1639-1645 (2001).
65. Linger, K. et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89, 4272-4279 (2004).
66. Fusco, A. et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol. 160, 2157-2167 (2002).
67. Santoro, M. et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest 89, 1517-1522 (1992).
68. Santoro, M. et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J. Clin. Endocrinol. Metab. 87, 370-379 (2002).
69. Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A. & Xu, X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103, 2261-2268 (2005).
70. Wirtschafter, A. et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107, 95-100 (1997).
71. Sheils, O. M., O'Eary J. J., Uhlmann, V., Lattich, K. & Sweeney, E. C. ret/PTC-1 activation in Hashimoto Thyroiditis. Int. J. Surg Pathol 8, 185-189 (2000).
72. Nikiforova, M. N., Caudill, C. M., Biddinger, P. & Nikiforov, Y. E. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 10, 15-22 (2002).
73. Fink, A., Tomlinson, G., Freeman, J. L., Rosen, I. B. & Asa, S. L. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod. Pathol. 9, 816-820 (1996).
74. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
75. Trovisco, V. et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 446, 589-595 (2005).
76. Trovisco, V. et al. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum. Pathol. 36, 694-697 (2005).
77. Namba, H. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88, 4393-4397 (2003).
78. Nikiforova, M. N. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404 (2003).
79. Soares, P. et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 444, 572-576 (2004).
80. Salvatore, G. et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 5175-5180 (2004).
81. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65, 4238-4245 (2005).
82. Lima, J. et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J. Clin. Endocrinol. Metab. 89, 4267-4271 (2004).
83. Nikiforova, M. N. et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 209, 1-6 (2004).
84. Rosenbaum, E. et al. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod. Pathol. 18, 898-902 (2005).
85. Kaplan, D. R., Martin-Zanca, D. & Parada, L. F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350, 158-160 (1991).
86. Martin-Zanca, D., Hughes, S. H. &Barbacid, M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319, 743-748 (1986).
87. Miller, F. D. & Kaplan, D. R. On Trk for retrograde signaling. Neuron 32, 767-770 (2001).
88. Wajjwalku, W. et al. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn. J. Cancer Res. 83, 671-675 (1992).
89. Bongarzone, I. et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81, 2006-2009 (1996).
90. Rabes, H. M. et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 6, 1093-1103 (2000).
91. Beimfohr, C., Klugbauer, S., Demidchik, E. P., Lengfelder, E. & Rabes, H. M. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int. J. Cancer 80, 842-847 (1999).
92. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
93. Lemoine, N. R. et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4, 159-164 (1989).
94. Namba, H., Rubin, S. A. & Fagin, J. A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4, 1474-1479 (1990).
95. Manenti, C., Pilotti, S., Re, F. C., Della Porta, G. & Pierotti, M. A. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur. J. Cancer 30A, 987-993 (1994).
96. Ezzat, S. et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6, 409-416 (1996).
97. Esapa, C. T., Johnson, S. J., Kendall-Taylor, P., Lennard, T. W. & Harris, P. E. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol (Oxford) 50, 529-535 (1999).
98. Basolo, F. et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10, 19-23 (2000).
99. Nikiforova, M. N. et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318-2326 (2003).
100. Shi, Y. F. et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 51, 2690-2693 (1991).
101. Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H. & Nikiforov, Y. E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 120, 71-77 (2003).
102. Suchy, B., Waldmann, V., Klugbauer, S. & Rabes, H. M. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br. J. Cancer 77, 952-955 (1998).
103. Hirokawa, M. et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am. J. Surg. Pathol. 26, 1508-1514 (2002).
104. Lloyd, R. V. et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am. J. Surg. Pathol. 28, 1336-1340 (2004).
105. Garcia-Rostan, G. et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21, 3226-3235 (2003). A thorough and meticulous report that demonstrates the relative infrequency of Ras mutations in activating MAPK signalling in well-differentiated thyroid carcinomas, along with the higher incidence of these mutations in poorly differentiated carcinomas.
106. Desvergne, B. & Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688 (1999).
107. Kroll, T. G. et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289, 1357-1360 (2000). An original description of the PPARγ rearrangement in follicular-type thyroid carcinomas.
108. Gregory Powell, J. et al. The PAX8-PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 23, 3634-3641 (2004).
109. Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G. & Nikiforov, Y. E. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol. 26, 1016-1023 (2002).
110. Marques, A. R. et al. Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 87, 3947-3952 (2002).
111. Cheung, L. et al. Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 88, 354-357 (2003).
112. Dwight, T. et al. Involvement of the PAX8-peroxisome proliferator- activated receptor gamma rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88, 4440-4445 (2003).
113. Castro, P., Roque, L., Magalhaes, J. & Sobrinho-Simoes, M. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARγ translocation. Int J. Surg Pathol 13, 235-238 (2005).
114. Thompson, N. W., Dunn, E. L., Batsakis, J. G. & Nishiyama, R. H. Hurthle cell lesions of the thyroid gland. Surg. Gynecol. Obstet. 139, 555-560 (1974).
115. Katoh, R., Harach, H. R. & Williams, E. D. Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J. Pathol. 186, 292-299 (1998).
116. Asa, S. L. My approach to oncocytic tumours of the thyroid. J. Clin. Pathol. 57, 225-232 (2004).
117. Cheung, C. C., Ezzat, S., Ramyar, L., Freeman, J. L. & Asa, S. L. Molecular basis of Hurthle cell papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 85, 878-882 (2000). The first paper to critically examine the molecular basis of the classification of oncocytic thyroid carcinomas.
118. Chiappetta, G. et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J. Clin. Endocrinol. Metab. 87, 364-369 (2002).
119. Maximo, V. & Sobrinho-Simoes, M. Mitochondrial DNA 'common' deletion in Hurthle cell lesions of the thyroid. J. Pathol. 192, 561-562 (2000).
120. Yeh, J. J. et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19, 2060-2066 (2000).
121. Maximo, V., Soares, P., Lima, J., Cameselle-Teijeiro, J. & Sobrinho-Simoes, M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol. 160, 1857-1865 (2002).
122. Petros, J. A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl Acad. Sci. USA 102, 719-724 (2005).
123. Shidara, Y. et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res. 65, 1655-1663 (2005).
124. Maximo, V. et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br. J. Cancer 92, 1892-1898 (2005).
125. Grose, R. & Dickson, C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16, 179-186 (2005).
126. Boelaert, K. et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 88, 2341-2347 (2003).
127. Logan, A., Black, E. G., Gonzalez, A. M., Buscaglia, M. & Sheppard, M. C. Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? Endocrinology 130, 2363-2372 (1992).
128. Isozaki, O. et al. Opposite regulation of deoxyribonucleic acid synthesis and iodide uptake in rat thyroid cells by basic fibroblast growth factor: correlation with opposite regulation of c-fos and thyrotropin receptor gene expression. Endocrinology 131, 2723-2732 (1992).
129. St Bernard, R. et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146, 1145-1153 (2005).
130. De Moerlooze, L. et al. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 127, 483-492 (2000).
131. Morikawa, Y. et al. Expression of the fibroblast growth factor receptor-1 in human normal tissues and tumors determined by a new monoclonal antibody. Arch. Pathol. Lab. Med. 120, 490-496 (1996).
132. Onose, H., Emoto, N., Sugihara, H., Shimizu, K. & Wakabayashi, I. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur. J. Endocrinol. 140, 169-173 (1999).
133. Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S. & Comoglio, P. M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155-156 (1989).
134. Ruco, L. P. et al. Expression of Met protein in thyroid tumours. J. Pathol. 180, 266-270 (1996).
135. Belfiore, A. et al. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J. Clin. Endocrinol. Metab. 82, 2322-2328 (1997).
136. Trovato, M. et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 8, 125-131 (1998).
137. Ruco, L. P., Stoppacciaro, A., Ballarini, F., Prat, M. & Scarpino, S. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J. Pathol. 194, 4-8 (2001).
138. Scarpino, S. et al. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J. Pathol. 199, 243-250 (2003).
139. Wasenius, V. M. et al. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am. J. Surg. Pathol. 29, 544-549 (2005).
140. Ivan, M., Bond, J. A., Prat, M., Comoglio, P. M. & Wynford-Thomas, D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14, 2417-2423 (1997).
141. Nardone, H. C. et al. c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer 98, 1386-1393 (2003).
142. Rubin, I. & Yarden, Y. The basic biology of HER2. Ann. Oncol. 12, S3-S8 (2001).
143. Kato, S. et al. Expression of erbB receptors mRNA in thyroid tissues. Biochim. Biophys. Acta 1673, 194-200 (2004).
144. Schiff, B. A. et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin. Cancer Res. 10, 8594-8602 (2004).
145. Holting, T., Siperstein, A. E., Clark, O. H. & Duh, Q. Y. Epidermal growth factor (EGF)- and transforming growth factor α-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur. J. Endocrinol. 132, 229-235 (1995).
146. Asmis, L. M., Gerber, H., Kaempf, J. & Studer, H. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J. Endocrinol. 145, 513-520 (1995).
147. Haugen, D. R., Akslen, L. A., Varhaug, J. E. & Lillehaug, J. R. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res. 56, 1184-1188 (1996).
148. Sugg, S. L. et al. Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clin. Endocrinol. (Oxford) 49, 629-637 (1998).
149. Akslen, L. A. & Varhaug, J. E. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76, 1643-1654 (1995).
150. Chen, B. K. et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int. J. Oncol. 15, 893-898 (1999).
151. Soh, E. Y. et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metab. 82, 3741-3747 (1997).
152. Klein, M. et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J. Endocrinol. 161, 41-49 (1999).
153. Bunone, G. et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 155, 1967-1976 (1999).
154. Tanaka, K. et al. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg. Today 32, 761-768 (2002).
155. Hung, C. J. et al. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J. Clin. Endocrinol. Metab. 88, 3694-3699 (2003).
156. Yasuoka, H. et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod. Pathol. 18, 1127-1133 (2005).
157. Hall, F. T., Freeman, J. L., Asa, S. L., Jackson, D. G. & Beasley, N. J. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol Head Neck Surg. 129, 716-719 (2003).
158. Katoh, R. et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum. Pathol. 30, 891-897 (1999).
159. Katoh, R. et al. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum. Pathol. 26, 139-146 (1995).
160. Basolo, F. et al. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br. J. Cancer 75, 537-541 (1997).
161. Yoshida, A. et al. Apoptosis and proliferative activity in thyroid tumors. Surg. Today 29, 204-208 (1999).
162. Volante, M., Croce, S., Pecchioni, C. & Papotti, M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod. Pathol. 15, 1038-1043 (2002).
163. Kjellman, P. et al. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 13, 371-380 (2003).
164. Basolo, F. et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 10, 741-746 (2000).
165. Lazzereschi, D. et al. Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int. J. Cancer 76, 806-811 (1998).
166. Zou, M., Shi, Y., Farid, N. R. & al-Sedairy, S. T. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine 8, 61-64 (1998).
167. Saiz, A. D. et al. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J. Pathol. 198, 157-162 (2002).
168. Brzezinski, J., Migodzinski, A., Gosek, A., Tazbir, J. & Dedecjus, M. Cyclin E expression in papillary thyroid carcinoma: relation to staging. Int. J. Cancer 109, 102-105 (2004).
169. Khoo, M. L., Ezzat, S., Freeman, J. L. & Asa, S. L. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J. Clin. Endocrinol. Metab. 87, 1810-1813 (2002).
170. Khoo, M. L., Beasley, N. J., Ezzat, S., Freeman, J. L. & Asa, S. L. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 87, 1814-1818 (2002).
171. Wang, S. et al. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod. Pathol. 13, 882-887 (2000).
172. Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma. Clin. Cancer Res. 11, 1037-1043 (2005).
173. WAF1/CIP1, a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br. J. Cancer 74, 1336-1341 (1996).
174. Resnick, M. B., Schacter, P., Finkelstein, Y., Kellner, Y. & Cohen, O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod. Pathol. 11, 735-739 (1998).
175. kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. Mod. Pathol. 13, 1014-1019 (2000).
176. Yane, K. et al. Lack of p16/CDKN2 alterations in thyroid carcinomas. Cancer Lett. 101, 85-92 (1996).
177. Tung, W. S. et al. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol. Carcinog. 15, 5-10 (1996).
178. INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83, 2185-2193 (1998).
179. Onda, M. et al. Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers. J. Hum. Genet. 49, 312-318 (2004).
180. Anwar, F., Emond, M. J., Schmidt, R. A., Hwang, H. C. & Bronner, M. P. Retinoblastoma expression in thyroid neoplasms. Mod. Pathol. 13, 562-569 (2000).
181. Ito, T. et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 52, 1369-1371 (1992).
182. Fagin, J. A. et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91, 179-184 (1993).
183. Donghi, R. et al. Gene p53 mutations are restricted to poorly
184. Dobashi, Y. et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn. Mol. Pathol. 3, 9-14 (1994).
185. Ho, Y. S., Tseng, S. C., Chin, T. Y., Hsieh, L. L. & Lin, J. D. p53 gene mutation in thyroid carcinoma. Cancer Lett. 103, 57-63 (1996).
186. Takeuchi, Y. et al. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid 9, 377-381 (1999).
187. Hosal, S. A. et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr. Pathol. 8, 21-28 (1997).
188. Brabant, G. et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res. 53, 4987-4993 (1993).
189. Scheumman, G. F. et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J. Clin. Endocrinol. Metab. 80, 2168-2172 (1995).
190. Kato, N., Tsuchiya, T., Tamura, G. & Motoyama, T. E-cadherin expression in follicular carcinoma of the thyroid. Pathol. Int. 52, 13-18 (2002).
191. Soares, P., Berx, G., van Roy, F. & Sobrinho-Simoes, M. E-cadherin gene alterations are rare events in thyroid tumors. Int. J. Cancer 70, 32-38 (1997).
192. Rocha, A. S. et al. E-cadherin loss rather than β-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42, 580-587 (2003).
193. Rocha, A. S. et al. Abnormalities of the E-cadherin-catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. J. Pathol. 194, 358-366 (2001).
194. Husmark, J., Heldin, N. E. & Nilsson, M. N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. Int. J. Cancer 83, 692-699 (1999).
195. Garcia-Rostan, G. et al. β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 158, 987-996 (2001). The first identified molecular alteration in poorly differentiated thyroid carcinomas, explaining the phenotype and behaviour.
196. Cerrato, A. et al. β- and γ-catenin expression in thyroid carcinomas. J. Pathol. 185, 267-272 (1998).
197. Ishigaki, K. et al. Aberrant localization of β-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J. Clin. Endocrinol. Metab. 87, 3433-3440 (2002).
198. Miyake, N. et al. Absence of mutations in the β-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol. Int. 51, 680-685 (2001).
199. Colletta, G. et al. Analysis of adenomatous polyposis coli gene in thyroid tumours. Br. J. Cancer 70, 1085-1088 (1994).
200. Cameselle-Teijeiro, J. et al. Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. Am. J. Clin. Pathol. 115, 486-493 (2001).
201. Harach, H. R., Williams, G. T. & Williams, E. D. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25, 549-561 (1994).
202. Soravia, C. et al. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am. J. Pathol. 154, 127-135 (1999).
203. Huang, Y. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl Acad. Sci. USA 98, 15044-15049 (2001). One of the earliest reports describing the use of gene-expression profiling to distinguish normal cells from neoplastic human papillary thyroid carcinoma cells.
204. Wasenius, V. M. et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res. 9, 68-75 (2003).
205. Yang, N. S., Kirkland, W., Jorgensen, T. & Furmanski, P. Absence of fibronectin and presence of plasminogen activator in both normal and malignant human mammary epithelial cells in culture. J. Cell Biol. 84, 120-130 (1980).
206. Ryu, S., Jimi, S., Eura, Y., Kato, T. & Takebayashi, S. Strong intracellular and negative peripheral expression of fibronectin in tumor cells contribute to invasion and metastasis in papillary thyroid carcinoma. Cancer Lett. 146, 103-109 (1999).
207. Liu, W., Asa, S. L. & Ezzat, S. 1α, 25-dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol. Endocrinol. 19, 2349-2357 (2005).
208. Cerutti, J. M. et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J. Clin. Invest. 113, 1234-1242 (2004).
209. Cheung, C. C., Carydis, B., Ezzat, S., Bedard, Y. C. & Asa, S. L. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J. Clin. Endocrinol. Metab. 86, 2187-2190 (2001). A key paper in defining the applications of molecular tools to pre-operative patient diagnosis and management.
210. Katoh, R. et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 70, 1585-1590 (1992).
211. Moniz, S. et al. Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur. J. Endocrinol. 146, 27-33 (2002).
212. Shattuck, T. M., Westra, W. H., Ladenson, P. W. & Arnold, A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352, 2406-2412 (2005).
213. Piersanti, M., Ezzat, S. & Asa, S. L. Controversies in papillary microcarcinoma of the thyroid. Endocr. Pathol. 14, 183-191 (2003).
214. Yano, Y. et al. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin. Cancer Res. 10, 2035-2043 (2004).
215. Hawthorn, L. et al. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck 26, 1069-1083 (2004).
216. Jarzab, B. et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 65, 1587-1597 (2005).
217. Takenaka, Y. et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 195, 111-119 (2003).
218. Cheung, C. C., Ezzat, S., Freeman, J. L., Rosen, I. B. & Asa, S. L. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 14, 338-342 (2001).
219. Saggiorato, E. et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr. Relat. Cancer 12, 305-317(2005).
220. Aldred, M. A. et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J. Clin. Oncol. 22, 3531-3539 (2004).
221. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 6, 358-362 (2006).
222. Rao, A. S. et al. Wnt/β-catenin signalling mediates anti-neoplastic effects of Imatinib mesylate (Glivec) in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 91, 159-168 (2006).
223. Kopp, P. et al. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J. Clin. Endocrinol. Metab. 79, 134-139 (1994).
224. Apel, R. L. et al. Clonality of thyroid nodules in sporadic goiter. Diagn. Mol. Pathol. 4, 113-121 (1995).
225. Jovanovic, L., Delahunt, B., McIver, B., Eberhardt, N. L. & Grebe, S. K. Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution. J. Clin. Endocrinol. Metab. 88, 3284-3291 (2003).
226. Martin, J. H. Neuroanatomy: Text and Atlas 2nd edn (Appleton & Lange, Stamford, Connecticut, 1996).